The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...

After hitting a record high in 2021, the number of biotech IPOs have fallen to a yearly average in the 20s, with most successful entries in the last few quarters involving companies with mid- to ...

The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Wednesday, April 2nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.50-$8.50 per share. The ...

The biotech is developing two candidates ... Another slice of the targeted IPO haul is earmarked for a proof-of-concept trial of F598, Alopexx’s other lead candidate. Sanofi licensed the ...

Sionna Therapeutics, a Waltham biotech targeting cystic fibrosis, raised $219.2 million in an IPO last month, and two other Bay State biotechs — Odyssey of Boston and Alopexx of Cambridge ...

DNA sequencing specialist’s decision to list in London in 2021 was seen as a victory for the market at the time ...

Judge rules in favor of Aurion in IPO suit, a decision investor Alcon ... and will be responding accordingly,” Alcon told Fierce Biotech in an emailed statement. “As Aurion’s largest ...

with more than 25 potential biotech IPOs considering market entry. Currently, 28 healthcare companies have filed for public listings in the U.S., with 19, or 68%, choosing Nasdaq as their ...

Kirkland, Wash.-based Kestra Medical Technologies is aiming to raise about $150 million in its initial public offering, pricing shares between $14 and $16 ...